Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel

Gynecologic Oncology

Volumn 63, Issue 1, 1996, Pages 89-93

  Shapiro, Jeremy D ^a   Millward, Michael J ^a   Rischin, Danny ^a   Michael, Michael ^a   Walcher, Vicki ^a   Francis, Prudence A ^a   Toner, Guy C ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NEUROPATHY; OVARY CANCER; PRIORITY JOURNAL; RASH;

EID: 0030272511     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0284     Document Type: Article

References (28)

1. Young, R. C., Perez, C. A., and Hoskins, W. J. Cancer of the ovary, in Cancer. Principles and Practice of Oncology (V. T. DeVita Jr., S. Hellman, and S. A. Rosenberg, Eds.), Lippincourt, Philadelphia, pp. 1231-1234 (1993).
2. Advanced Ovarian Clinical Trials Group. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials, Br. Med. J. 303, 884-893 (1991).
3. Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., and Lewis, J. L., Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, J. Clin. Oncol. 9, 389-393 (1991).
4. Markman, M., and Hoskins, W. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population, J. Clin. Oncol. 10, 513-514 (1992).
5. Thigpen, J. T., Vance, R. B., and Khansur, T. Second-line chemotherapy for recurrent carcinoma of the ovary, Cancer 71, 1559-1564 (1993).
6. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med. 111, 273-279 (1989).
7. Trimble, E. L., Adams, J. D., Vena, D., Hawkins, M. J., Friedman, M. A., Fisherman, J. S., Christian, M. C., Canetta, R., Onetto, N., and Hayn, R. Paclitaxel for refractory ovarian cancer: Results for the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103, J. Clin. Oncol. 11, 2405-2410 (1993).
8. Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S. M., Rothenberg, M., Adamo, D. O., Davis, P., Ognibene, F. P., Cunnion, R. E., and Reed, E. Dose-intense Taxol. High response rates in patients with platinum resistant recurrent ovarian cancer, J. Natl. Cancer Inst. 86, 18-24 (1994).
9. Phillips, K. A., Friedlander, M., Olver, I., Evans, B., Smith, J., Fitz-harris, B., McCrystal, M., Joughin, J., and Bishop, J. Australasian multicentre phase II study of paclitaxel in relapsed ovarian cancer, Aust. N.Z. J. Med. 25, 337-343 (1995).
10. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334, 1-6 (1996).
11. Heinemann, V., Hertel, L. W., Grindley, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′2′-difluorodeoxycytidine and 1βD-arabinofuranosylcytosine, Cancer Res. 48, 4024-4031 (1988).
12. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, E. C., and Grindley, G. B. Evaluation of the antitumor activity of Gemcitabine, Cancer Res. 50, 4417-4422 (1990).
13. Kaye, S. B. Gemcitabine: Current status of phase I and II trials [editorial], J. Clin. Oncol. 12, 1527-1531 (1994).
14. Le Chevalier, T., Gottfried, M., Gatzemeier, U., Shepherd, F. A., Weynants, P., Cottier, B., Groen, M. J. M., Rosso, R., Mattson, K., Cortes-Funes, H., Tonato, M., and Voi, M. Confirmatory activity of gemcitabine in non-small cell lung cancer, Eur. J. Cancer 29A, s160 (1993).
15. Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., and Rugg, T. A. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study, J. Clin. Oncol. 12, 1535-1540 (1994).
16. Cornier, Y., Eisenhauer, E., Muldal, A., Gregg, R., Ayoub, J., Goss, G., Stewart, D., Tarasoff, P., and Wong, D. Gemcitabine is an active agent in previously untreated extensive small cell lung cancer, Ann. Oncol. 5, 283-285 (1994).
17. Carmichael, J., Possinger, K., Philip, P., Beykirch, M., Kerr, H., Walling, J., and Harris, A. Advanced breast cancer: A phase II trial with gemcitabine, J. Clin. Oncol. 13, 2731-2736 (1995).
18. Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, D. P., Brown, T. D., Flombaum, C. D., Trochanowski, B., and Tarasoff, P. G. Phase II study of gemcitabine in patients with adenocarcinoma of the pancreas, Invest. New Drugs 12, 29-34 (1994).
19. Catimel, G., Vermerken, K. B., Clavel, M., deMulder, P., Judson, I., Sessa, C., Piccart, M., Bruntsch, U., Verweij, J., and Wanders, J. A phase II study of gemcitabine in patients with advanced squamous cell carcinoma of the head and neck, Ann. Oncol. 5, 543-547 (1994).
20. Lund, B., Hansen, O. P., Theilade, K., Hansen, M., and Neijt, J. P. Phase II study of gemcitabine (2′2′-difluorodeoxycytidine) in previously treated ovarian cancer patients, J. Natl. Cancer Inst. 86, 1530-1533 (1994).
21. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment, Cancer, 47, 207-214 (1981).
22. Allerheiligen, S., Johnson, R., Hatcher, B., Freeman, K., Tarasoff, P., Voi, M., and Dorr, A. Gemcitabine pharmacokinetics are influenced by gender, body surface area, and duration of infusion, Proc. Am. Soc. Clin. Oncol. 13, 136 (abstract 339) (1994).
23. Hillcoat, B. L., Campbell, J. J., Pepperell, R., Quinn, M. A., Bishop, J. F., and Day, A. Phase II trial of VP-16-213 in advanced ovarian carcinoma, Gynecol. Oncol. 22, 162-166 (1985).
24. Horkins, P. J., and Swenerton, K. D. Oral etoposide is active against platinum resistant ovarian cancer, J. Clin. Oncol. 12, 60-63 (1994).
25. Kudelka, A., Edwards, C., Freedman, R., Wallin, B., Hord, M., Howell, E., Harper, K., Raber, M., and Kavanagh, J. An open phase II study to evaluate the efficacy and toxicity of Topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma, Proc. Am. Soc. Clin. Oncol. 12, 259 (abstract 821) (1993).
26. Kavanagh, J., Tresukosol, D., Edwards, C., Freedman, R., Gonzalez de Leon, C., Fishman, A., Mante, R., Hard, M., and Kudelka, A. Carboplatin re-induction after Taxane in patients with platinum-refractory epithelial ovarian cancer, J. Clin. Oncol. 13, 1584-1588 (1995).
27. Steward, W. P., Dunlop, D. J., Cameron, C., Talbot, D. C., Kleisbauer, J. P., Thomas, P., Guerin, J. C., Perol, M., Sanson, C., Dabouis, G., and Lacroix, H. Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer, Proc. Am. Soc. Clin. Oncol. 14, 351 (abstract 1064) (1995).
28. Carmichael, J., Allerheiligen, S., and Walling, J. A Phase I/II study of gemcitabine and carboplatin in NSCLC, Proc. Am. Soc. Clin. Oncol. 14, 351 (abstract 1065) (1995).